2019 Review and Looking Forward

 
2019 Review and Looking Forward
 
Last year began with a strategic review of our brands, capabilities and international partners, which ultimately led to a restructured product portfolio, a host of new international partnerships and an expansion of our corporate, sales and medical teams.
 

New Ready-to-Use Caldolor is Designed to Help Address National Opioid Crisis.

 

We are very pleased to announce that the national launch of our FDA-approved Next Generation Caldolor product!

 

Caldolor was originally approved in a vial presentation. The new formulation of Caldolor comes in a ready-to-use, pre-mixed bag containing 800 mg of ibuprofen in a patented formulation. This new presentation will provide healthcare professionals with a formulation that is ready to use and easy to administer. It’s the first and only FDA-approved pre-mixed bag of ready-to-use, injectable ibuprofen.

 

Cumberland Emerging Technologies Appoints a New Senior Executive

 
Cumberland Emerging Technologies, or CET, is a joint initiative between Cumberland Pharmaceuticals, Vanderbilt University, LaunchTN, and Winhealth Pharma Group. Its mission is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace.
 

Orphan Drug Grant Funding for New Clinical Program!

 
We’ve initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). Based on pre-clinical findings, the U.S. FDA has cleared our application to study ifetroban in DMD patients, 7 years of age and older.
 

Vibativ®, Acetadote®, Caldolor® and Methotrexate Update

 

Earlier this year, we announced a strategic review following our accelerated business development activities, that led toa series of transactions. Because of that progress, we took a fresh look at our portfolio, partners and organization to ensure we havethe proper focus and capabilities going forward. Below is a summary of our findings and decisions: